Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
refractory mantle cell lymphoma
.
Show all posts
Showing posts with label
refractory mantle cell lymphoma
.
Show all posts
Friday, March 1, 2024
FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
›
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), announced the U.S. Food and Drug Administration (FDA) approved Jaypirc...
Monday, February 22, 2016
Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma
›
In continuation of my update on Ibrutinib and Temsirolimus Temsirolimus Phase III trial findings suggest that patients with relap...
›
Home
View web version